Interestingly, the serum protein clusterin ameliorates the pro-inflammatory phenotype of BECs in a rodent model of AD, which suggests that this molecule could be useful in AD treatment by targeting the BBB [187]. This evidence concerns the gene CLU and Alzheimer disease.